



Proxy (to proxy holder other than notary)¹

**for the Annual General Meeting of Shareholders (“AGM”)
of Vivoryon Therapeutics N.V. (the “Company”)
to be held on
Wednesday, June 21, 2023, at 1:00 p.m. CEST**

The undersigned:

Surname, First Name(s) of the Shareholder

Address, City, Postcode, Country

Number of Shares

Registration Number

hereby grants full power of attorney to:

Surname, First Name(s) of the proxy holder

Address, City, Postcode, Country

to on behalf of the undersigned (i) attend the AGM in person, (ii) sign the attendance list, (iii) address the meeting, (iv) vote its/their shares in respect of the items on the agenda in accordance with the voting instructions below, and (v) generally act as proxy of the undersigned at the AGM.

City, Date

Signature

My/our voting right for my/our registered number of shares is to be exercised as per the voting instructions issued below. If no voting instruction or a conflicting voting instruction is given in this proxy for any or all of the agenda items, I/we shall be deemed to have instructed the proxy holder to vote in favor of the relevant agenda item(s).²

¹ The completed proxy form should be received for organizational reasons until **Wednesday, June 14, 2023, 06:00 p.m. (CEST)** at the following address, or e-mail address: Vivoryon Therapeutics N.V., c/o Computershare Operations Center, 80249 München, Germany; e-mail: anmeldestelle@computershare.de. The completed and signed proxy form must be shown at registration for the meeting.

² If you do not wish to exercise a vote regarding any or all of the agenda items, you are kindly requested to tick “abstention” with respect to the relevant agenda item(s).

VOTING INSTRUCTIONS

	AGENDA ITEM	YES	NO	ABSTENTION
3	Remuneration report	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4	2022 annual accounts	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6	Release from liability of the Company's executive directors	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7	Release from liability of the Company's non-executive directors	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
8	Remuneration policy	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
9	Appointment of Kugan Sathiyandarajah as non-executive member of the Board	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
10	Appointment of Morten Asser Karsdal as non-executive member of the Board	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
11	Re-appointment of external auditor	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
12	Authorization to acquire own shares	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>